Moderna (MRNA) Financial Analysis & Valuation | Quarter Chart
Moderna (MRNA)
MRNAPrice: $47.61
Fair Value: 🔒
🔒score
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its r... more
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therap... more
Description
Shares
| Market Cap | $18.89B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Stéphane Bancel |
| IPO Date | 2018-12-07 | CAGR | 0.38% |
| Employees | 5,800 | Website | www.modernatx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
MRNA chart loading...
Fundamentals
Technicals
| Enterprise Value | $19.75B | P/E Ratio | -5.85 |
| Forward P/E | -14.54 | PEG Ratio | — |
| P/S Ratio | 8.52 | P/B Ratio | 2.55 |
| P/CF Ratio | -13.05 | P/FCF Ratio | -11.98 |
| EPS | $-8.14 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -29.12% | Gross Margin | -0.14% |
| Operating Margin | -1.53% | Profit Margin | -1.44% |
| ROE | -0.37% | ROA | -0.28% |
| ROCE | -0.38% | Current Ratio | 2.41 |
| Quick Ratio | 2.35 | Cash Ratio | 0.8 |
| Debt/Equity | 0.18 | Interest Coverage | -189.56 |
| Altman Z Score | 3.12 | Piotroski Score | 1 |